INTERVENTIONAL VASCULAR CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

25 Jul 2017

Vancouver’s EVA Vein Care Now Offers New Varicose Vein Treatment

Minimally Invasive Non-Surgical Procedure Now Available in Time for Summer

26 Jan 2017

New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians

BTG International Canada Inc., part of global specialist healthcare company BTG (LSE: BTG), today announced the Canadian commercial launch of Varithena™ (polidocanol injectable foam), a drug/device combination product used to treat varicose veins.

26 Jan 2017

Nouveau traitement des varices offrant une intervention non chirurgicale à effraction minimale pour les Canadiens

BTG International Canada Inc., qui fait partie de BTG, une entreprise internationale de soins de santé spécialisés (LSE : BTG), a annoncé aujourd’hui le lancement sur le marché canadien de Varithena™ (mousse injectable à base de polidocanol), une combinaison de médicament et d’appareil utilisé pour traiter les varices.

9 Jan 2017

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system.

BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system.

24 Aug 2015

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension, in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment.

11 Aug 2014

First Varicose Vein Patient Treated with FDA-Approved Varithena® (polidocanol injectable foam) 1%

BTG International Inc. announces that the first varicose vein patient has been treated with Varithena®

11 Jun 2014

EKOS Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announces the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS® System (ACCESS PTS) Study.

Interventional Vascular